{
    "clinical_study": {
        "@rank": "46874", 
        "arm_group": [
            {
                "arm_group_label": "NVA237", 
                "arm_group_type": "Experimental", 
                "description": "NVA237 inhaled via the Breezhaler\u00ae device once daily"
            }, 
            {
                "arm_group_label": "Tiotropium", 
                "arm_group_type": "Active Comparator", 
                "description": "Tiotropium 5\u03bcg inhaled via the Respimat\u00ae device once daily"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the  Efficacy of NVA237 (50 \u03bcg o.d) using tiotropium (5\u03bcg \u03bcg o.d) as\n      active control in COPD patients."
        }, 
        "brief_title": "Efficacy of NVA237 (50 \u03bcg o.d) Using Tiotropium (5\u03bcg \u03bcg o.d) as Active Control in COPD Patients.", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Disease, Chronic Obstructive", 
        "condition_browse": {
            "mesh_term": [
                "Chronic Disease", 
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "A 52-week treatment, multicenter, randomized, open-label, parallel-group study to assess the\n      efficacy of NVA237 (50\u03bcg once daily) using Tiotropium (5\u03bcg once daily) as an active control\n      in Brazilian patients with moderate to severe Chronic Obstructive Pulmonary Disease."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion:\n\n          -  Men and women aged 40 years or over.\n\n          -  History of current or former smoking of at least 10 pack-years\n\n          -  Cooperative outpatients, with a COPD diagnosis established by the measurement of\n             FEV1/FVC < 0.7 post-bronchodilation in basal spirometry (without use of medication or\n             post-washout). Moderate to severe stage patients will be included, with\n             post-bronchodilator FEV1 between 30 and 80% of the normal value according to GOLD\n             2011 since the inclusion criteria in this trial will be based on spirometry results.\n\n        Exclusion:\n\n          -  Pregnant women or nursing mothers\n\n          -  History of asthma at visit 1 indicated by, but not limited to:\n\n               -  Onset of respiratory symptoms suggestive of asthma (such as coughing, wheezing,\n                  shortness of breath) before the age of 40.\n\n               -  History of diagnosed asthma\n\n          -  History of respiratory tract infection within six weeks prior to Visit 1.\n\n          -  History of hospitalization or emergency care for a COPD exacerbation in the 3 months\n             prior to Visit 1.\n\n          -  Subjects who require use of home oxygen therapy.\n\n          -  Patients in the active phase of an assisted pulmonary rehabilitation program and\n             patients who completed the rehabilitation program within 18 months from Visit 1 or 2\n             of the protocol.17,20\n\n          -  Patients with known history and diagnosis of alpha-1 antitrypsin deficiency.\n\n          -  Patients with concomitant lung disease, e.g.: tuberculosis (unless confirmed by\n             radiography as inactive) or clinically significant bronchiectasis.\n\n          -  Patients who in the investigator's judgment have an abnormality or significant\n             medical condition such as: unstable ischemic heart disease, left ventricular failure,\n             history of myocardial infarction, arrhythmia (except chronic stable atrial\n             fibrillation), history of malignancy of any system (including lung cancer) treated or\n             not within the last 5 years, glaucoma, prostatic hyperplasia, moderate to severe\n             renal impairment, urinary retention, any other condition that might compromise\n             patient safety or compliance, interfere with the evaluations, or prevent the\n             termination of their participation in the study.\n\n          -  Patients with contraindications to tiotropium or ipratropium treatment or who have\n             experienced undesirable reactions with inhaled anticholinergic agents or patients\n             with a history of an undesirable reaction with sympathomimetic amines or inhaled\n             medication with any of those components, or a history of hypersensitivity to any of\n             the study medications, including rescue medication, or similar classes of medication.\n\n          -  Patients using tiotropium, long-acting anticholinergics, short-acting\n             anticholinergics, fixed combinations of inhaled beta agonists and inhaled\n             corticosteroids, theophylline. In these cases, the patient is allowed, after agreeing\n             to participate in the study, to enter a washout period from Visit\n\n          -  Patients using inhaled steroids, alone or as an exchange in a fixed combination at\n             equivalent doses, unless on a stable treatment for at least 1 month prior to\n             randomization\n\n          -  Patients using nonselective beta-blockers.\n\n          -  Patients using cromoglycate, nedocromil, ketotifen and leukotriene antagonists unless\n             on stable treatment for at least 1 month prior to randomization .\n\n          -  Patients who used oral prednisone (or equivalent) over a long period, defined as \u2265 10\n             mg/day for at least 1 month prior to Visit 1\n\n          -  Patients who used intramuscular depot corticosteroids within 30 days from Visit 1.\n\n          -  Patients with a history of long QT Syndrome or with prolonged QTc (> 450 ms) measured\n             at Visit 1 (Fridericia Method).\n\n          -  Patients who, in the opinion of the investigator, have clinically significant\n             abnormalities on ECG. These patients should not be re-screened.\n\n          -  Other exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "340", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01837927", 
            "org_study_id": "CNVA237ABR01"
        }, 
        "intervention": [
            {
                "arm_group_label": "NVA237", 
                "description": "Once daily for 52 weeks", 
                "intervention_name": "NVA237", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tiotropium", 
                "description": "Once daily for 52 weeks", 
                "intervention_name": "Tiotropium Respimat\u00ae", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tiotropium"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Efficacy,  NVA237, Tiotropium, Chronic Obstructive Pulmonary Disease, COPD", 
        "lastchanged_date": "January 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Salvador", 
                        "country": "Brazil", 
                        "state": "BA", 
                        "zip": "40110-060"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fortaleza", 
                        "country": "Brazil", 
                        "state": "CE", 
                        "zip": "60864-190"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vitoria", 
                        "country": "Brazil", 
                        "state": "ES", 
                        "zip": "29055-450"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Goiania", 
                        "country": "Brazil", 
                        "state": "GO", 
                        "zip": "74110-030"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Belo Horizonte", 
                        "country": "Brazil", 
                        "state": "MG", 
                        "zip": "30130-100"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Belo Horizonte", 
                        "country": "Brazil", 
                        "state": "MG", 
                        "zip": "30150-281"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Recife", 
                        "country": "Brazil", 
                        "state": "PE", 
                        "zip": "50920-640"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rio de Janeiro", 
                        "country": "Brazil", 
                        "state": "RJ", 
                        "zip": "22271-100"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rio de Janeiro", 
                        "country": "Brazil", 
                        "state": "RJ", 
                        "zip": "22280-020"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rio de Janeiro", 
                        "country": "Brazil", 
                        "state": "RJ", 
                        "zip": "20551-030"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Novo Hamburgo", 
                        "country": "Brazil", 
                        "state": "RS", 
                        "zip": "93510-250"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil", 
                        "state": "RS", 
                        "zip": "90035-903"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil", 
                        "state": "RS", 
                        "zip": "90880-480"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil", 
                        "state": "RS", 
                        "zip": "90020-060"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil", 
                        "state": "RS", 
                        "zip": "90610-000"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil", 
                        "state": "RS", 
                        "zip": "90020-090"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Florianopolis", 
                        "country": "Brazil", 
                        "state": "SC", 
                        "zip": "88040-970"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ribeirao Preto", 
                        "country": "Brazil", 
                        "state": "SP", 
                        "zip": "14048-900"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil", 
                        "state": "SP", 
                        "zip": "04101-000"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil", 
                        "state": "SP", 
                        "zip": "04039-004"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "S\u00e3o Bernardo do Campo", 
                        "country": "Brazil", 
                        "state": "SP", 
                        "zip": "09750-420"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "S\u00e3o Paulo", 
                        "country": "Brazil", 
                        "state": "SP", 
                        "zip": "04023-062"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "S\u00e3o Paulo", 
                        "country": "Brazil", 
                        "state": "SP", 
                        "zip": "01244-030"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "S\u00e3o Paulo", 
                        "country": "Brazil", 
                        "state": "SP", 
                        "zip": "01224-000"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "S\u00e3o Paulo", 
                        "country": "Brazil", 
                        "state": "SP", 
                        "zip": "05403-000"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 52-week Treatment, Multi-center, Randomized, Open Label, Parallel Group Study to Assess the Efficacy of NVA237 (50 \u03bcg o.d.) Using Tiotropium (5 \u03bcg o.d.) as an Active Control in Brazilian Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.", 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": "ANVISA BRAZIL ':' (Brazilian Health Surveillance Agency)"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. FEV1 will be measured by spirometry. A positive change from baseline in FEV1 indicates improvement in lung function.", 
            "measure": "Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 12 weeks after treatment."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01837927"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. FEV1 will be measured by spirometry. A positive change from baseline in FEV1 indicates improvement in lung function.", 
                "measure": "Forced Expiratory Volume in 1 Second (FEV1) at day 1", 
                "safety_issue": "No", 
                "time_frame": "30 and 60 minutes post-dose on the first day of study treatment."
            }, 
            {
                "description": "Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. FEV1 will be measured by spirometry. A positive change from baseline in FEV1 indicates improvement in lung function.", 
                "measure": "Forced Expiratory Volume in 1 Second (FEV1) at day 7 and weeks 12, 24 and 52", 
                "safety_issue": "No", 
                "time_frame": "30 and 60 minutes post-dose on the 7th day of study treatment and at weeks 12, 24 and 52"
            }, 
            {
                "description": "Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. FEV1 will be measured by spirometry. A positive change from baseline in FEV1 indicates improvement in lung function.", 
                "measure": "Forced Expiratory Volume in 1 Second (FEV1) at weeks 24 and 52", 
                "safety_issue": "No", 
                "time_frame": "pre-dose at weeks 24 and 52 of study treatment"
            }, 
            {
                "description": "Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry. A positive change from baseline in FVC indicates improvement in lung function.", 
                "measure": "Change From Baseline in Forced Vital Capacity (FVC)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 7, weeks 12, 24 and 52 of study treatment"
            }, 
            {
                "description": "Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry. A positive change from baseline in FVC indicates improvement in lung function.", 
                "measure": "FEV1 AUC 0-4h", 
                "safety_issue": "No", 
                "time_frame": "05, 30, 60 minutes and 4 hours post-dose at days 1, 7 and week 12"
            }, 
            {
                "description": "All AEs and SAEs will be reported", 
                "measure": "Safety and tolerance of NVA237", 
                "safety_issue": "Yes", 
                "time_frame": "52 weeks"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}